BACKGROUND: HIV-1 infection is characterized by an inverted CD4/CD8 T-cell ratio, but the distribution of inversions over time after seroconversion and whether delay of inversion is associated with a favorable prognosis are not known. METHODS: T-cell counts and clinical outcomes among men in the Multicenter AIDS Cohort Study who had incident HIV-1 infection before December 31, 1995 were analyzed by Kaplan-Meier and Cox proportional hazards methods. Results were also analyzed by time-dependent multivariate methods to adjust for CD4 lymphocyte counts, viral loads, age, race, and polymorphisms in host chemokine receptor genes (CCR5-Delta32 and CCR2-64I). RESULTS: Among 424 cases whose date of seroconversion was known to within +/-4.5 months, 317, 52, and 55 inverted their CD4/CD8 ratio within less than 1, 1 to 2, and more than 2 years of seroconversion, respectively. Longer time to inversion was significantly associated with longer time to AIDS, even after adjusting for CD4 lymphocyte count and viral load at the first seropositive visit and over the first 3 seropositive visits. Of the 6 seroconverters who had more than 500 CD4 lymphocytes 10 years after seroconversion without receiving highly active antiretroviral therapy, 5 took more than 2 years to invert their CD4/CD8 ratio. CONCLUSIONS: Time from HIV-1 seroconversion to inversion of the CD4/CD8 ratio independently predicted time to AIDS. Early measurements of the CD4/CD8 ratio until inversion occurs may identify people likely to become long-term nonprogressors or slow progressors, thus facilitating detailed studies of the mechanism of HIV-1 disease progression.
BACKGROUND:HIV-1 infection is characterized by an inverted CD4/CD8 T-cell ratio, but the distribution of inversions over time after seroconversion and whether delay of inversion is associated with a favorable prognosis are not known. METHODS: T-cell counts and clinical outcomes among men in the Multicenter AIDS Cohort Study who had incident HIV-1 infection before December 31, 1995 were analyzed by Kaplan-Meier and Cox proportional hazards methods. Results were also analyzed by time-dependent multivariate methods to adjust for CD4 lymphocyte counts, viral loads, age, race, and polymorphisms in host chemokine receptor genes (CCR5-Delta32 and CCR2-64I). RESULTS: Among 424 cases whose date of seroconversion was known to within +/-4.5 months, 317, 52, and 55 inverted their CD4/CD8 ratio within less than 1, 1 to 2, and more than 2 years of seroconversion, respectively. Longer time to inversion was significantly associated with longer time to AIDS, even after adjusting for CD4 lymphocyte count and viral load at the first seropositive visit and over the first 3 seropositive visits. Of the 6 seroconverters who had more than 500 CD4 lymphocytes 10 years after seroconversion without receiving highly active antiretroviral therapy, 5 took more than 2 years to invert their CD4/CD8 ratio. CONCLUSIONS: Time from HIV-1 seroconversion to inversion of the CD4/CD8 ratio independently predicted time to AIDS. Early measurements of the CD4/CD8 ratio until inversion occurs may identify people likely to become long-term nonprogressors or slow progressors, thus facilitating detailed studies of the mechanism of HIV-1 disease progression.
Authors: Hemant Kulkarni; Jason F Okulicz; Greg Grandits; Nancy F Crum-Cianflone; Michael L Landrum; Braden Hale; Glenn Wortmann; Edmund Tramont; Michael Polis; Matthew Dolan; Alan R Lifson; Brian K Agan; Sunil K Ahuja; Vincent C Marconi Journal: J Acquir Immune Defic Syndr Date: 2011-08-15 Impact factor: 3.731
Authors: Joseph B Margolick; Jean M Da Costa Castro; Albert Sanchez; Francois Gemrot; John P Phair; Beth D Jamieson; Charles R Rinaldo; Lisa P Jacobson Journal: AIDS Res Hum Retroviruses Date: 2010-04 Impact factor: 2.205
Authors: Arpi S Terzian; Susan Holman; Niyati Nathwani; Esther Robison; Kathleen Weber; Mary Young; Ruth M Greenblatt; Stephen J Gange Journal: J Womens Health (Larchmt) Date: 2009-12 Impact factor: 2.681
Authors: Erik S Van Dis; Tyler C Moore; Kerry J Lavender; Ronald J Messer; Oliver T Keppler; Jens Verheyen; Ulf Dittmer; Kim J Hasenkrug Journal: Virology Date: 2015-11-21 Impact factor: 3.616
Authors: Nathalia Holt; Jianbin Wang; Kenneth Kim; Geoffrey Friedman; Xingchao Wang; Vanessa Taupin; Gay M Crooks; Donald B Kohn; Philip D Gregory; Michael C Holmes; Paula M Cannon Journal: Nat Biotechnol Date: 2010-07-02 Impact factor: 54.908
Authors: Jean-Michel Molina; Birgit Grund; Fred Gordin; Ian Williams; Mauro Schechter; Marcello Losso; Matthew Law; Ernest Ekong; Noluthando Mwelase; Athanasios Skoutelis; Martin J Wiselka; Linos Vandekerckhove; Thomas Benfield; David Munroe; Jens D Lundgren; James D Neaton Journal: Lancet HIV Date: 2018-01-16 Impact factor: 16.070
Authors: Jianming Tang; Xuelin Li; Matthew A Price; Eduard J Sanders; Omu Anzala; Etienne Karita; Anatoli Kamali; Shabir Lakhi; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour Journal: Front Microbiol Date: 2015-07-01 Impact factor: 5.640
Authors: Victor Leung; Jennifer Gillis; Janet Raboud; Curtis Cooper; Robert S Hogg; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Sean B Rourke; Chris Tsoukas; Marina B Klein Journal: PLoS One Date: 2013-10-30 Impact factor: 3.240